"Globally Unique" Product Can't Mask $1B Loss: Chinese Vascular Intervention "Unicorn" Pushes for IPO
H&H Healthcare
R&D and Producer of Interventional Medical Devices for Heart Disease
Source: Medical Device Distributors Alliance
Reposting without authorization is prohibited; reposting is only permitted after 24 hours!
Holding the world's only
Domestic “Unicorn” Medical Device Company Races Toward IPO!
Recently, according to the Shanghai Stock Exchange, a cardiovascular medical device unicorn company—Shanghai H&H Healthcare Technology Company Ltd.(hereinafter referred to as “H&H Healthcare”) STAR MarketListing Application Accepted, officially embarking on the final push toward its IPO. This IPO is jointly sponsored by Soochow Securities and Guotai Haitong Securities.Raised RMB 1.11 billion in funds.
It is understood that H&H Healthcare, established only six years ago, is an innovative medical device company focused on the field of pan-vascular intervention, with its business coveringStructural Heart Interventions, Vascular Interventions, and Oncology InterventionsThe Three Major High-End Pan-Vascular Interventional Fields.
Multiple Products from the Company AchieveDomestic First-of-its-Kind, Breaking Import MonopolyAmong them, the K-Clip transcatheter tricuspid annuloplasty system, approved in March 2025, holds the world’s only registration certificate.
H&H Healthcare has consistently garnered recognition from both the capital markets and the industry, driven by its robust research and development capabilities.
In April this year, Boston Scientific and H&H Healthcare officially signed an agreement,Boston ScientificWillingness to PayRMB 10 Million Acquisition Option Deposit, obtaining the right to acquire H&H Healthcare’s IVL business vehicle for a consideration of RMB 225 million by December 31, 2027.
Furthermore, the company has undergone eight rounds of financing, with investors includingYuanhe Origin, Boyuan Capital, SDIC Chuanghe, Guofang Capitaland other well-known institutions, with cumulative financingOver RMB 2 billionand was awarded the title of "Shanghai Key Service Unicorn (Potential) Enterprise."
With the launch of its IPO, can this domestic “unicorn” seize the momentum and carve out a place for Chinese innovative forces in the international market?
Revenue Soars, Yet Losses Hit 700 Million
Can H&H Healthcare Successfully IPO?
From the perspective of corporate product portfolio, leveraging substantial R&D investment, H&H Healthcare hasInterventional Cardiac Valve Procedures, Vascular Interventions, Electrophysiology Interventions, Drug Delivery Interventions, and Intelligent Interventionsand other fields, demonstrating remarkable strength and breakthroughs.
Furthermore, the company has successfully established four major platforms: R&D and manufacturing of delivery systems, clinical medical technology, precision manufacturing, and global marketing, achieving a transition fromFull Industry Chain Layout from R&D to Market。
As of the date of signing the prospectus, its core product K-Clip has been domesticallyOver 100 End-User HospitalsAchieve commercial implantation, coveringZhongshan Hospital Affiliated to Fudan University, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Beijing Anzhen Hospital, Xiangya Hospital of Central South University, and other medical institutions.
Multi-product portfolio layout, core products implanted in 100 hospitals, alliance with Boston Scientific... From a product perspective, H&H Healthcare has entered the stage of commercial scale-up.
However, the financial data in the prospectus also clearly revealsThe Other Side of the Enterprise:
According to the prospectus data, from 2023 to 2025, H&H Healthcare’s revenue surged from RMB 2.8037 million to RMB 102 million, representing a nearly 36-fold increase over three years, with significantly accelerated commercialization. However, the net profit attributable to shareholders of the parent company was respectively-201 million yuan, -190 million yuan, and -219 million yuan.
As of the end of 2025, the company's accumulated uncoveredLosses reached 738 million yuan, its core business is completely unable to generate internal cash flow.
In addition, the company's operating activities generatedNet cash flow also remained consistently negative. From 2023 to 2025, the net cash flows from operating activities of the Company were respectively-98.046 million yuan, -73.9687 million yuan, -55.3829 million yuan.
It is evident that although H&H Healthcare has entered the stage of commercial scale-up for its products, it still has some way to go before product sales can cover R&D, marketing, and operational costs.
Perhaps this is also the essence of H&H Healthcare's forceful push for an IPO, through1.1 billion yuan raised to sustain operations through capital infusion.As planned, thisRMB 430 million for building a production base, RMB 210 million for new product R&D, RMB 220 million for overseas market expansion, and RMB 250 million for supplementing working capital.Scale up commercialization through an initial public offering.
The Commercialization Dilemma of Domestic Medical Device Companies: How to Break Through?
The Gap Between Capital and Reality at H&H Healthcare Exposes China's Heart Valve MarketCommercialization Dilemma.
In terms of R&D capabilities, the gap between domestic companies such as H&H Healthcare and foreign giants in the current tricuspid valve treatment market is continuously narrowing, with both parties even standing on the same starting line in certain niche segments.
However, in practice,Domestic Medical Device EnterprisesTo truly achieve transcendence, one must still undergo the test.Commercialization Implementation Capability.
On the one hand, there is the widespread adoption of surgical procedures.Domestic companies cannot merely sell medical devices; they must also invest capital and effort to train physicians on their use.
On the other hand, there is pricing and payment.New technologies are often expensive. If they are not included in the coverage lists of public medical insurance or commercial health insurance, patients face substantial out-of-pocket costs, which directly limits the volume of surgeries performed.
For domestic innovative medical device companies such as H&H Healthcare, the “gap” between revenue and profit is not a signal of failure, but rather the growing pains of an industry maturing. It compels companies to"Laboratory mindset" completely shifts to "business mindset".
Whoever can be the first to successfully establish the pathway from technological leadership to a closed-loop commercial model will truly secure victory in the domestic substitution landscape.
